caa a22 4500 469121882 CHVBK 20180323133141.0 cr unu---uuuuu 170328e19920401xx s 000 0 eng 10.1007/BF02244821 doi (NATIONALLICENCE)springer-10.1007/BF02244821 Effects of zolpidem and flunitrazepam on nocturnal sleep of women subjectively complaining of insomnia [Elektronische Daten] [A. Declerck, F. Ruwe, J. O'Hanlon, A. Wauquier] Eighteen non-pregnant woman complaining about insomnia were polysomnographically investigated for 3 nights with weekly intervals. They received placebo, 2 mg flunitrazepam or 10 mg zolpidem according to a cross-over double blind design. The patients were selected by general practitioners on the basis of subjective complaints. Zolpidem is a recently introduced short-acting imidazopyridine hypnotic, binding to a subunit of the benzodiazepine 1 receptor. Flunitrazepam is a well-known hypnotic, binding to both the benzodiazepine 1 and 2 receptor subtypes. Objective recording did not substantiate the subjective complaint of insomnia. Sleep patterns during placebo differed only little from that expected from age matched healthy persons. Both flunitrazepam and zolpidem significantly shortened sleep onset (5 min of continuous sleep beginning with NREM 1 sleep). The sleep composition following flunitrazepam was characterized by an increase in NREM 2, a prolongation of the time to REM sleep, a reduction of REM sleep and an increase in NREM 3-4 sleep during the first 2 h of sleep. The sleep composition following zolpidem resembled more that seen in persons without sleep complaints. However, as compared to placebo, there was a decrease of the time spent awake during sleep and an increase in NREM 3-4 during the first 2 of sleep. Springer-Verlag, 1992 Zolpidem nationallicence Flunitrazepam nationallicence Insomnia nationallicence Polysomnography nationallicence Women nationallicence Declerck A. Department of EEG and Clinical Neurophysiology, Epilepsy Center Kempenhaeghe, NL-Heeze, The Netherlands aut Ruwe F. Department of EEG and Clinical Neurophysiology, Epilepsy Center Kempenhaeghe, NL-Heeze, The Netherlands aut O'Hanlon J. Institute for Drugs, Safety and Behavior, University of Maastricht, NL-Maastricht, The Netherlands aut Wauquier A. Department of Neurology, Medical College of Ohio, P.O. Box 10008, 43699, Toledo, OH, USA aut Psychopharmacology Springer-Verlag 106/4(1992-04-01), 497-501 0033-3158 106:4<497 1992 106 213 https://doi.org/10.1007/BF02244821 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02244821 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Declerck A. Department of EEG and Clinical Neurophysiology, Epilepsy Center Kempenhaeghe, NL-Heeze, The Netherlands aut NATIONALLICENCE 700 1- Ruwe F. Department of EEG and Clinical Neurophysiology, Epilepsy Center Kempenhaeghe, NL-Heeze, The Netherlands aut NATIONALLICENCE 700 1- O'Hanlon J. Institute for Drugs, Safety and Behavior, University of Maastricht, NL-Maastricht, The Netherlands aut NATIONALLICENCE 700 1- Wauquier A. Department of Neurology, Medical College of Ohio, P.O. Box 10008, 43699, Toledo, OH, USA aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 106/4(1992-04-01), 497-501 0033-3158 106:4<497 1992 106 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence SWISSBIB 46911908X BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer